A Germline Test to Uncover Your Hereditary & Familial Cancer Risk
OncoRisk® is a comprehensive, AI-powered hereditary cancer test designed to identify genetic mutations associated with more than 11 distinct hereditary and familial cancers. Built for both oncologists and patients, this test provides insights that enable early detection, informed decision-making, and proactive care planning for individuals and families at risk.
Your Genetic Shield Against Hereditary Cancers
Some cancers run in families. With a 74-gene panel covering the most relevant hereditary risk markers, OncoRisk® offers a science-backed way to uncover elevated risk across a broad spectrum of cancers—empowering clinicians and patients to take timely action with confidence.
Covers 74 genes linked to 11+ hereditary and familial cancers
Supports both affected patients and unaffected family members
Enables informed surgical decisions (e.g. prophylactic mastectomy)
Offers AI-powered reporting with personalized risk interpretation
Includes pre- and post-test genetic counseling for patients
Designed for actionable screening, prevention, and surveillance
How It Works
Genetic Sample Collection
A simple blood sample is collected for germline DNA extraction.
NGS-Based Germline Sequencing
Our test uses deep sequencing of 74 high-priority cancer-related genes.
AI-Powered Interpretation
Reports are generated via the iCare™ platform and delivered with clear risk classifications and clinical action points.
Genetic Counseling Support
Patients receive guidance to interpret the report and discuss next steps.
Applications
For Clinicians & Oncology Teams
Identify hereditary risk in affected patients and their relatives
Initiate personalized screening and risk reduction plans
Guide decisions on prophylactic surgery and early surveillance
For Individuals and Families
Understand inherited cancer risk and act early
Enable proactive health and lifestyle choices
Support family members in genetic risk assessment
Why Choose OncoRisk®?
- Broad panel covering risk across major hereditary and familial cancers
- Actionable insights for real-world clinical decision-making
- AI-enhanced reports with clear classifications and intervention paths
- Backed by genetic counseling to support patients and families
- Enables cascade testing across at-risk family members
Key Actionable Genes
Breast
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1 , MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, POLD1, POLE, PTEN, RADSO, RAD51C, RAD51D, SMARCA4, STK11, TP53
Pancreas
APC, ATM, BRCA1, BRCA2, BMPR1A, CDK4, CDKN2A, EPCAM, MLH1, MSH2, MSH6, PALB2, PMS2, SMAD4, STK11, TP53
Ovary
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, TP53, STK11
Renal
BAP1,FH, FLCN,MET, PTEN, SDHA, SDHB, SDHC, SDHD, TSC1, TSC2, TP53, VHL
Colorectal
APC, BMPR1A, CDH1, CHEK2, EPCAM, GREM1, MLH1, MSH2, MSH6, MUTYH, PMS2, POLD1, POLE, PTEN, SMAD4, STK11, TP53, AXIN2, NTHL1, MSH3
Skin
BAP1, BRCA2, CDK4, CDKN2A, EPCAM, FH, FLCN, MLH1, MIFT, MSH2, MSH6, PMS2, PTEN, TERT,TP53
Gastrointestinal
APC, BMPR1A, CDH1, CTNNA1, EPCAM, MLH1, MSH2, MSH6, PMS2, SMAD4, STK11, TP53
Endocrine
MEN1, RET
Prostate
ATM, BRCA1, BRCA2, CHEK2, ЕРСАМ, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, PTEN, RAD51D, TP53
Lung
EGFR, STK11
